Institute of Collective Health, Federal University of Bahia, Salvador, Brazil.
Center for Data and Knowledge Integration for Health (CIDACS), Fiocruz, Salvador, Brazil.
Respir Res. 2020 Jul 11;21(1):178. doi: 10.1186/s12931-020-01439-4.
Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.
卡介苗(BCG)接种在许多低收入和中等收入国家(LMIC)是常规且近乎普遍的。有人认为 BCG 可能对 COVID-19 的发病率和死亡率有保护作用。本评论讨论了围绕 BCG 和 COVID-19 的证据的局限性。我们认为,需要更高质量的证据来从现有二次数据中了解 BCG 疫苗的保护作用,同时我们等待目前在不同环境中进行的临床试验的结果。